(5-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}-3-pyridyl)methan-1-ol | 330795-75-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (5-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}-3-pyridyl)methan-1-ol
• 英文别名: [5-[3-(5-Chloro-2-phenylmethoxyphenyl)thiophen-2-yl]pyridin-3-yl]methanol
• CAS: 330795-75-0
• 化学式: C₂₃H₁₈ClNO₂S
• 分子量: 407.92
• InChiKey: BCNFLWJPXFQVHV-UHFFFAOYSA-N

物化性质

• 沸点：
  517.4±45.0 °C(Predicted)
• 密度：
  1.302±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  70.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}-3-pyridyl)methan-1-ol 在 manganese(IV) oxide 作用下， 以72%的产率得到5-[3-(2-Benzyloxy-5-chloro-phenyl)-thiophen-2-yl]-pyridine-3-carbaldehyde
  参考文献：
  名称：

  2,3-Diarylthiophenes as selective EP1 receptor antagonists

  摘要：

  The synthesis and the EPI receptor binding affinity of 2,3-diarylthiophene derivatives are described. The evaluation of the structure-activity relationship (SAR) in this series led to the identification of compounds 4, 7, and 12a, which exhibit high affinity for the human EPI receptor and a selectivity greater than 100-fold against the EP2, EP3, EP4, DP, FP, and IP receptors and greater than 25-fold versus the TP receptor. These three antagonists present good pharmacokinetics in rats and significant differences in the way they are distributed in the brain. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.005
• 作为产物：
  描述：

  2-溴-4-氯苯酚 在 sodium tetrahydroborate 、 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 tris(dibenzylideneacetone)dipalladium (0) 、 三苯胂 、 potassium carbonate 作用下， 生成 (5-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}-3-pyridyl)methan-1-ol
  参考文献：
  名称：

  2,3-Diarylthiophenes as selective EP1 receptor antagonists

  摘要：

  The synthesis and the EPI receptor binding affinity of 2,3-diarylthiophene derivatives are described. The evaluation of the structure-activity relationship (SAR) in this series led to the identification of compounds 4, 7, and 12a, which exhibit high affinity for the human EPI receptor and a selectivity greater than 100-fold against the EP2, EP3, EP4, DP, FP, and IP receptors and greater than 25-fold versus the TP receptor. These three antagonists present good pharmacokinetics in rats and significant differences in the way they are distributed in the brain. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.005

文献信息

• Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
  申请人：Merck Frosst Canada & Co.

  公开号：US06369082B1

  公开（公告）日：2002-04-09

  This invention encompasses the novel compounds of formula A, which are useful in the treatment of prostaglandin mediated diseases, or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases.

  这项发明涵盖了公式A的新化合物，这些化合物在治疗前列腺素介导的疾病方面具有用途，或其药用可接受的盐、水合物或酯。该发明还涵盖了用于治疗前列腺素介导疾病的药物组合物和方法。
• CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
  申请人：Merck Frosst Canada & Co.

  公开号：EP1216241A1

  公开（公告）日：2002-06-26
• US6369082B1
  申请人：——

  公开号：US6369082B1

  公开（公告）日：2002-04-09
• [EN] CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT<br/>[FR] ACIDES CARBOXYLIQUES ET ACYLSULFONAMIDES, COMPOSITIONS CONTENANT DE TELS COMPOSES ET METHODES DE TRAITEMENT
  申请人：MERCK FROSST CANADA INC

  公开号：WO2001019819A2

  公开（公告）日：2001-03-22

  This invention encompasses the novel compounds of formula (A), which are useful in the treatment of prostaglandin mediated diseases, or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases.